13 completed, 4 withdrawn, 3 unknown, 2 active not recruiting. 25 Phase 3, 6 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 25 | Completed 13, Withdrawn 4, Unknown 3, Active not recruiting 2, Terminated 2, Enrolling by invitation 1 |
| Phase 2 | 6 | Completed 2, Unknown 2, Active not recruiting 1, Terminated 1 |
Follow SOC: new trials by email Literature Review of SOC trials Research Report on SOC
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Geriatric Oncology Care in Brazil: Remote Geriatric Assessment-Driven Interventions With Supportive Care GAIN-S Multidisciplinary Telehealth Intervention, Standard Oncology Care - Geriatric Assessment, Geriatric Oncology | Phase 3 | Enrolling by invitation | Cristiane Decat Bergerot, PhD | 350 | 2024-12-06 | 2025-07-24 |
| Trial to Evaluate Nitazoxanide for Treatment of Mild or Moderate COVID-19 in Subjects at High Risk of Severe Illness Nitazoxanide, Vitamin Super-B Complex, Placebo - COVID-19 | Phase 3 | Withdrawn | Romark Laboratories L.C. | 2024-08-01 | 2024-09-24 | |
| Clinical Study for the Efficacy and Safety of Ropeginterferon Alfa-2b in Adult COVID-19 Patients With Comorbidities Ropeginterferon alfa-2b, SOC - COVID-19 | Phase 2 / Phase 3 | Unknown | National Taiwan University Hospital | 60 | 2023-05-15 | 2023-04-11 |
| Precision-T: A Randomized Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies Orca-T, Standard-of-Care - Acute Myeloid Leukemia, Acute Lymphoid Leukemia | Phase 3 | Active not recruiting | Orca Biosystems, Inc. | 187 | 2022-06-21 | 2026-03-04 |
| Daunorubicin or Idarubicin With Cytarabine Plus Quizartinib vs Physician's Choice in Newly Diagnosed FLT3-ITD+ AML Quizartinib, Treatment according to Physician's Choice, Standard of Care Chemotherapy - Acute Myeloid Leukemia | Phase 3 | Withdrawn | University Hospital Heidelberg | 2022-05-01 | 2022-05-25 | |
| DTG/3TC Fixed Dose Formulations for the Maintenance of Virological Suppression in Children With HIV Infection Aged 2 to <15 Years Old Dolutegravir (DTG) and lamivudine (3TC), SOC - HIV Infections | Phase 2 / Phase 3 | Active not recruiting | PENTA Foundation | 386 | 2022-04-22 | 2026-03-04 |
| Clinical Study for the Efficacy and Safety of Ropeginterferon Alfa-2b in Moderate COVID19. P1101 (Ropeginterferon alfa-2b), SOC - COVID-19 | Phase 3 | Completed | National Taiwan University Hospital | 134 | 2022-04-01 | 2024-04-16 |
| Study to Evaluate Efficacy and Safety of Switching to VM-1500A-LAI + 2NRTIs From the 1st Line Standard of Care Therapy VM-1500A-LAI, Standard of Care - HIV-1-infection | Phase 2 / Phase 3 | Unknown | Viriom | 438 | 2022-04-01 | 2022-01-24 |
| MNK-6105 for Patients With Cirrhosis and High Ammonia Levels Affecting Brain Function MNK-6105, Placebo, Standard of Care - Hepatic Encephalopathy | Phase 3 | Withdrawn | Mallinckrodt | 2021-11-01 | 2021-09-22 | |
| A Study to Evaluate the Efficacy and Safety of Proxalutamide (GT0918) in Hospitalized COVID-19 Subjects GT0918, Standard of care, Matching placebo - Covid19 | Phase 3 | Terminated | Suzhou Kintor Pharmaceutical Inc, | 139 | 2021-09-30 | 2023-08-18 |
| EFFICACY and SAFETY OF BEVACIZUMAB (ZIRABEV®) IN PATIENTS WITH SEVERE HYPOXEMIC COVID-19 BEVA+SOC, SOC - Corona Virus Infection, SARS (Severe Acute Respiratory Syndrome) | Phase 3 | Completed | Assistance Publique - Hôpitaux de Paris | 96 | 2021-04-17 | 2022-12-28 |
| The Impact of Fecal Microbiota Transplantation as an Immunomodulation on the Risk Reduction of COVID-19 Disease Progression With Escalating Cytokine Storm and Inflammatory Parameters Human fecal microbiota, MBiotix HBI, Placebo, SOC - Covid19 | Phase 3 | Unknown | Medical University of Warsaw | 366 | 2021-04-01 | 2021-04-01 |
| Phase 3 Study to Assess Resiniferatoxin vs Standard of Care for the Treatment of Intractable Cancer Pain Resiniferatoxin, Standard of Care - Pain, Intractable, Pain Cancer | Phase 3 | Withdrawn | Sorrento Therapeutics, Inc. | 2020-12-01 | 2021-11-09 | |
| A Study to Evaluate Efficacy and Safety of PTC299 (Emvododstat) in Hospitalized Participants With Coronavirus (COVID-19) PTC299, SOC, Placebo - Pneumonia, COVID-19 | Phase 2 / Phase 3 | Terminated | PTC Therapeutics | 189 | 2020-07-09 | 2023-06-26 |
| Efficacy + Safety of Liposome Cyclosporine A to Treat Bronchiolitis Obliterans Post Single Lung Transplant (BOSTON-1) Liposomal Cyclosporine A, standard of care - Bronchiolitis Obliterans, Chronic Rejection of Lung Transplant | Phase 3 | Completed | Zambon SpA | 62 | 2019-03-26 | 2025-10-27 |
| Efficacy + Safety of Liposome Cyclosporine A to Treat Bronchiolitis Obliterans Post Double Lung Transplant (BOSTON-2) Liposomal Cyclosporine A, Standard of Care - Bronchiolitis Obliterans, Chronic Rejection of Lung Transplant | Phase 3 | Completed | Zambon SpA | 169 | 2019-03-26 | 2026-02-10 |
| Study to Assess the Efficacy and Safety of Ryanodex as Adjuvant Treatment in Subjects With EHS Ryanodex and Standard of Care, Standard of Care - Exertional Heat Stroke | Phase 3 | Completed | Eagle Pharmaceuticals, Inc. | 17 | 2018-08-19 | 2021-05-19 |
| Long-term Safety and Efficacy Study of Teduglutide in Pediatric Participants With Short Bowel Syndrome (SBS) TED, SOC, Syringe - Short Bowel Syndrome | Phase 3 | Completed | Shire | 61 | 2017-01-09 | 2025-03-28 |
| Long-term Study of Teduglutide in Pediatric Subjects With Short Bowel Syndrome Who Completed the TED-C13-003 Study Teduglutide, SOC - Short Bowel Syndrome | Phase 3 | Completed | Shire | 29 | 2016-12-09 | 2025-03-19 |
| ODYSSEY (PENTA 20) Dolutegravir, Standard of Care - HIV Infection | Phase 2 / Phase 3 | Completed | PENTA Foundation | 792 | 2016-09-20 | 2025-07-29 |
Showing 20 of 25. Sign in to see all of them.
COVID-19 (6) · HIV Infections (3) · Asthma (2) · Bronchiolitis Obliterans (2) · Clostridium Infections (2) · Coronavirus Infections (2) · Leukemia, Myeloid, Acute (2) · Pulmonary Eosinophilia (2) · Rejection, Psychology (2) · Short Bowel Syndrome (2) · Cancer Pain (1) · Coronaviridae Infections (1) · Depression (1) · Hepatic Encephalopathy (1) · Hypoxia (1)
PENTA Foundation (3) · GlaxoSmithKline (2) · Merck Sharp & Dohme LLC (2) · National Taiwan University Hospital (2) · Shire (2) · Zambon SpA (2) · Assistance Publique - Hôpitaux de Paris (1) · Cristiane Decat Bergerot, PhD (1) · Eagle Pharmaceuticals, Inc. (1) · Mallinckrodt (1) · Medical University of Warsaw (1) · Orca Biosystems, Inc. (1) · PTC Therapeutics (1) · Romark Laboratories L.C. (1) · Sorrento Therapeutics, Inc. (1)
United Kingdom (9) · United States (9) · Spain (8) · France (7) · Belgium (6) · Germany (5) · South Africa (5) · Ukraine (4) · Argentina (3) · Canada (3) · Italy (3) · Portugal (3) · Russia (3) · Thailand (3) · Uganda (3)
Paola Castellani, MD (2) · Adrian Hepner (1) · Anastasia Pokrovskaya, PhD (1) · Diana Gibb (1) · Monica Luchi, MD (1) · Quintus Ngumah, OD, PhD (1) · Richard F Schlenk, Prof Dr (1) · Wang-Huei Sheng, M.D. Ph.D (1)
PMID 28121498, PMID 29538686, PMID 29788418, PMID 30060024, PMID 30227108, PMID 30455246, PMID 30460321, PMID 31411386, PMID 31628838, PMID 32099847, PMID 32376702, PMID 32504314, PMID 36661328, PMID 38873891, PMID 41858082, PMID 27316794, PMID 28395936, PMID 29949045, PMID 31047111, PMID 31251094, PMID 31507641, PMID 31846705, PMID 31883370, PMID 32101275, PMID 32763217, PMID 33446115, PMID 33848093, PMID 34098955, PMID 34158028, PMID 34817414, PMID 34965338, PMID 35868341, PMID 36055295, PMID 36906440, PMID 37304494, PMID 37766218, PMID 37766505, PMID 38010606, PMID 38636725, PMID 39978387, PMID 41385341, PMID 41579881, PMID 42806776
2014 (2), 2016 (2), 2018 (2), 2019 (1)